Transaction · 0000874015-26-000062

BENNETT C FRANK

BENNETT C FRANK, EVP, CSO, reported a transaction classified as grant at IONIS PHARMACEUTICALS INC involving 9675.000000 shares for an estimated $0.00. Reported holdings after the transaction were 27109.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code AEVP, CSO
IONSIONIS PHARMACEUTICALS INC
Filing timeJan 20
Trade dateJan 15, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$77.53
Pre-filing
1mo ago +1.1%1w ago +5.2%1d ago +1.7%
Returns since
7d +5.9%30d +7.2%90d -3.4%180d -29.8%1y -17.6%

IONS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
IONS since 2026-01-20Filed 227 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0000874015-26-000062
Restricted Stock Unit
Transaction date
Jan 15, 2026
Filed Jan 20, 2026, 12:00 AM · 5d delay
Shares
9.67k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
27.1k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-10score
Filing-only score

-10

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP, Chief Scientific Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

  2. F2

    The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

  3. F3

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.14 to $75.18 inclusive. The reporting person undertakes to prov…

  4. F4

    Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

  5. F5

    The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The num…

  6. F6

    Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

  7. F7

    Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Compa…

  8. F8

    Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Original filing · 0000874015-26-000062
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

IONS